We obtained primary leukemic cells from both Ph+ CML and ALL patients, of which the baseline information, such as Bcr/Abl variant type, drug resistance, and mutations including Tp53 mutations, is presented in Table1, and treated them with PMIBcr/Abl‐R6, Bcr/Abl‐R6, imatinib, or nutlin‐3 (Figure7A). Here, ABL1 is linked to acute lymphoblastic leukemia.